Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) Director Ilan Ganot sold 2,658 shares of the firm's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $5.82, for a total transaction of $15,469.56. Following the sale, the director directly owned 27,474 shares in the company, valued at approximately $159,898.68. The trade was a 8.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Ilan Ganot also recently made the following trade(s):
- On Wednesday, February 4th, Ilan Ganot sold 7,205 shares of Solid Biosciences stock. The shares were sold at an average price of $6.44, for a total transaction of $46,400.20.
- On Wednesday, January 28th, Ilan Ganot sold 191 shares of Solid Biosciences stock. The stock was sold at an average price of $6.59, for a total transaction of $1,258.69.
- On Monday, January 5th, Ilan Ganot sold 1,053 shares of Solid Biosciences stock. The stock was sold at an average price of $5.43, for a total value of $5,717.79.
Solid Biosciences Stock Up 7.6%
SLDB opened at $5.92 on Thursday. The firm has a market cap of $461.23 million, a price-to-earnings ratio of -2.38 and a beta of 2.67. Solid Biosciences Inc. has a 52 week low of $2.41 and a 52 week high of $7.37. The business's 50 day moving average is $5.95 and its two-hundred day moving average is $5.68.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on SLDB. Barclays set a $9.00 price target on Solid Biosciences and gave the company an "overweight" rating in a research report on Tuesday, November 4th. JPMorgan Chase & Co. cut their price target on shares of Solid Biosciences from $13.00 to $11.00 and set an "overweight" rating for the company in a report on Wednesday, November 5th. Needham & Company LLC reaffirmed a "buy" rating and issued a $16.00 target price on shares of Solid Biosciences in a report on Monday, February 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. Finally, Chardan Capital restated a "buy" rating and set a $15.00 target price on shares of Solid Biosciences in a report on Tuesday, November 4th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $14.70.
Read Our Latest Research Report on Solid Biosciences
Institutional Investors Weigh In On Solid Biosciences
Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc grew its holdings in Solid Biosciences by 208.6% in the second quarter. Legal & General Group Plc now owns 6,011 shares of the company's stock valued at $29,000 after purchasing an additional 4,063 shares during the period. Ameritas Investment Partners Inc. increased its stake in Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock worth $33,000 after acquiring an additional 4,534 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Solid Biosciences by 142.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company's stock worth $63,000 after purchasing an additional 5,991 shares during the period. Creative Planning purchased a new stake in shares of Solid Biosciences during the 2nd quarter worth about $57,000. Finally, Police & Firemen s Retirement System of New Jersey grew its holdings in shares of Solid Biosciences by 233.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company's stock worth $74,000 after purchasing an additional 10,585 shares during the period. Institutional investors and hedge funds own 81.46% of the company's stock.
Key Stories Impacting Solid Biosciences
Here are the key news stories impacting Solid Biosciences this week:
- Neutral Sentiment: Coverage explaining the intraday lift — AAII published an item titled "Why Solid Biosciences Inc.’s (SLDB) Stock Is Up 7.64%" that summarizes market reaction and likely drivers for the rise; read it for context. Why SLDB Stock Is Up
- Neutral Sentiment: Technical and valuation context: 12‑month range roughly $2.41–$7.37, market cap ≈ $461M, negative P/E (loss-making), 50‑day SMA ~$5.95 and 200‑day SMA ~$5.68 — the stock is trading near its recent highs, so momentum/coverage can amplify moves.
- Negative Sentiment: CEO Alexander Cumbo sold 16,644 shares at an average $5.82 (≈ $96,868); his post‑sale holding is 235,405 shares (down ~6.6%). Filing: CEO Sale Filing
- Negative Sentiment: CFO Kevin Tan sold 5,404 shares at an average $5.82 (≈ $31,451); post‑sale holding 99,422 shares (down ~5.2%). Filing: CFO Sale Filing
- Negative Sentiment: COO David T. Howton sold 7,469 shares at $5.82 (≈ $43,470); post‑sale holding 105,077 shares (down ~6.6%). Filing: COO Sale Filing
- Negative Sentiment: CTO Paul Herzich sold 3,616 shares at $5.82 (≈ $21,045); post‑sale holding 72,638 shares (down ~4.7%). Filing: CTO Sale Filing
- Negative Sentiment: Director Ilan Ganot sold 2,658 shares at $5.82 (≈ $15,470); post‑sale holding 27,474 shares (down ~8.8%). Filing: Director Sale Filing
- Negative Sentiment: Insider Jessie Hanrahan sold 4,134 shares at $5.82 (≈ $24,060); post‑sale holding 74,318 shares (down ~5.3%). Filing: Insider Sale Filing
Solid Biosciences Company Profile
(
Get Free Report)
Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company's primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.
Solid's lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
